Oragenics, Inc. Announces Approval To Initiate Phase II Concussion Drug Trial in Australia
UF Innovate | Accelerate graduate Oragenics announced that it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate a Phase II clinical trial evaluating ONP-002 for the treatment of mild traumatic brain injury (mTBI).
Oragenics, Inc. To Participate at the 15th Annual Traumatic Brain Injury Conference
UF Innovate | Accelerate graduate Oragenics, Inc., a biotechnology company developing novel intranasal therapies for concussion and other brain-related conditions, announced its participation in the 15th Annual Traumatic Brain Injury Conference.
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury
UF Innovate | Accelerate graduate Oragenics, Inc. announced the submission of its Investigator’s Brochure (IB) application in preparation for its Phase II clinical trial using ONP-002 in Australia.
Oragenics, Inc. Announces Partnership With BRAINBox Solutions To Revolutionize Concussion Diagnosis and Treatment
UF Innovate | Accelerate graduate Oragenics, Inc., a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, announced a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI).
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
UF Innovate | Accelerate graduate Oragenics, Inc., a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced its lead candidate for treating concussion successfully completed a study that indicates ONP-002 does not cause cardiotoxicity.
Odyssey Group International’s Planned Acquisition of Concussion Drug from Prevacus, Inc. Enhances Delivery Capabilities with Nasal Therapeutic
Odyssey Group International is circulating a video to better define its drug candidate PRV-002, a therapeutic compound drug to treat concussion (mild traumatic brain injury (mTBI), from UF Innovate | Sid Martin Biotech alum Prevacus Inc. Odyssey is expected to acquire PRV-002 by the end of February.
